Investors should take note of NYSE:HAE, a growth stock that remains attractively priced.

Last update: Aug 6, 2024

Our stock screener has spotted HAEMONETICS CORP/MASS (NYSE:HAE) as a growth stock which is not overvalued. NYSE:HAE is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. We'll dive into each aspect below.

Growth Analysis for NYSE:HAE

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NYSE:HAE has received a 7 out of 10:

The Earnings Per Share has grown by an impressive 31.35% over the past year.
Measured over the past years, HAE shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.74% on average per year.
Looking at the last year, HAE shows a quite strong growth in Revenue. The Revenue has grown by 12.01% in the last year.
Based on estimates for the next years, HAE will show a very strong growth in Earnings Per Share. The EPS will grow by 21.40% on average per year.
Based on estimates for the next years, HAE will show a quite strong growth in Revenue. The Revenue will grow by 10.74% on average per year.
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.

A Closer Look at Valuation for NYSE:HAE

ChartMill assigns a Valuation Rating to every stock. This score ranges from 0 to 10 and evaluates the different valuation aspects and compares the price to earnings and cash flows, while taking into account profitability and growth. NYSE:HAE scores a 6 out of 10:

HAE's Price/Earnings ratio is rather cheap when compared to the industry. HAE is cheaper than 83.77% of the companies in the same industry.
HAE is valuated rather cheaply when we compare the Price/Earnings ratio to 28.44, which is the current average of the S&P500 Index.
83.25% of the companies in the same industry are more expensive than HAE, based on the Price/Forward Earnings ratio.
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of HAE indicates a rather cheap valuation: HAE is cheaper than 81.68% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of HAE indicates a rather cheap valuation: HAE is cheaper than 83.77% of the companies listed in the same industry.
The excellent profitability rating of HAE may justify a higher PE ratio.
A more expensive valuation may be justified as HAE's earnings are expected to grow with 16.88% in the coming years.

Understanding NYSE:HAE's Health

ChartMill assigns a Health Rating to every stock. This score ranges from 0 to 10 and evaluates the different health aspects like liquidity and solvency, both absolutely, but also relative to the industry peers. NYSE:HAE scores a 5 out of 10:

An Altman-Z score of 3.53 indicates that HAE is not in any danger for bankruptcy at the moment.
HAE's Altman-Z score of 3.53 is fine compared to the rest of the industry. HAE outperforms 69.63% of its industry peers.
With a decent Debt to FCF ratio value of 7.00, HAE is doing good in the industry, outperforming 75.92% of the companies in the same industry.
A Current Ratio of 2.56 indicates that HAE has no problem at all paying its short term obligations.

How do we evaluate the Profitability for NYSE:HAE?

ChartMill's Profitability Rating offers a unique perspective on stock analysis, providing scores from 0 to 10. These ratings consider a wide range of profitability metrics and margins, both in comparison to industry peers and on their own merits. For NYSE:HAE, the assigned 9 is a significant indicator of profitability:

HAE's Return On Assets of 5.35% is amongst the best of the industry. HAE outperforms 85.34% of its industry peers.
HAE has a better Return On Equity (12.24%) than 86.91% of its industry peers.
The Return On Invested Capital of HAE (8.55%) is better than 87.96% of its industry peers.
The 3 year average ROIC (7.51%) for HAE is below the current ROIC(8.55%), indicating increased profibility in the last year.
HAE has a Profit Margin of 8.98%. This is amongst the best in the industry. HAE outperforms 83.25% of its industry peers.
HAE's Profit Margin has improved in the last couple of years.
Looking at the Operating Margin, with a value of 15.57%, HAE belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
HAE's Operating Margin has improved in the last couple of years.
HAE's Gross Margin has improved in the last couple of years.

More Affordable Growth stocks can be found in our Affordable Growth screener.

For an up to date full fundamental analysis you can check the fundamental report of HAE

Disclaimer

Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.